Search

Search results

1. Canada should permanently expand drug approval process in post-COVID world

   Accepting FDA approvals could lead to earlier marketing availability in Canada. ...

2. Environmental appraisals for new gene therapies may limit new drugs in Canada

   Appeared in Calgary's Business, June 5, 2020 The Trudeau government plans to move ahead with major revisions in regulations governing the tribunal that sets ceiling prices for new prescription drugs in Canada. Revisions include replacing countries ...

3. Ottawa’s changes to drug-pricing will deny some Canadians potentially lifesaving drugs

   Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable. ...

4. New U.S. laws threaten Canada's pharmaceutical drug supply

   Appeared in the Hill Times, June 9, 2019 Lawmakers in 16 U.S. states have introduced bills to make legal the wholesale importation of pharmaceutical products from Canada. Vermont already has a law on the books and governors in Florida and Colorado plan to ...

5. Government's pharmacare plan raises more questions than answers

   Appeared in the Toronto Sun, March 30, 2019 The latest federal budget revealed the Trudeau government’s plan to move forward on national pharmacare. The problem, however, is that the government still hasn’t outlined exactly what it means by “national ...

6. Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare

   Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good. ...

7. Increasing barriers for drug manufacturers may ultimately hurt patients

   Appeared in the Moncton Times & Transcript, August 31, 2018 The Trudeau government has proposed major changes to the role of the Patent Medicine Prices Review Board (PMPRB), whose primary function is to ensure that maximum Canadian prices for patented ...

8. Ottawa’s revisions to drug-pricing review board will delay or prevent access to new drugs

   Appeared in the Hamilton Spectator, January 19, 2018 Last May, the former federal Health Minister Jane Philpott announced proposed changes to the Patented Medicine Prices Review Board (PMPRB) designed "to protect Canadians from excessive drug prices. ...

9. Ottawa’s proposed changes to review board will reduce access to prescription drugs

   Appeared in the Winnipeg Free Press, July 6, 2017 In a speech in May, federal Health Minister Jane Philpott talked about rising prescription drug prices and announced the launch of consultations on proposed changes to the Patented Medicine Prices Review ...

10. Pharmacare: be careful what you wish for

    Appeared in the New Brunswick Telegraph-Journal, October 29, 2015 Almost 60 per cent of respondents to a recent poll thought that a national Pharmacare program would be good for Canadians. National Pharmacare appears to be regarded by many as a panacea ...